nach oben

International Journal of Colorectal Disease

Erschienen in:

01.02.2010 | Original Article

Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy

verfasst von: Antonia M. Fernández-Peralta, Lydia Daimiel, Nargisse Nejda, Daniel Iglesias, Vicente Medina Arana, Juan J. González-Aguilera

Erschienen in: International Journal of Colorectal Disease | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

The enzyme MTHFR plays an important role in folate metabolism, and folate is implicated in carcinogenesis due to its role in DNA methylation, repair, and synthesis. We analyze the relationship of MTHFR C677T and A1298C polymorphisms with biological, clinicopathological, genetic and epigenetic features of tumors, and the patient outcome after treatment with 5-FU-based chemotherapy to determine the contribution of MTHFR genotypes in the risk of colorectal cancer (CRC) and in the response to therapy.

Methods

Genomic DNA of 143 Spanish sporadic CRC and 103 controls was analyzed by polymerase chain reaction/restriction fragment length polymorphism and sequencing.

Results

The C677T polymorphism has protective effect on CRC showing TT genotype an odds ratios of 0.06 (95% confidence interval (CI): 0.10–0.32) and the CT of 0.51 (95% CI: 0.3–0.87). MTHFR A1298C polymorphism is not associated with CRC risk. Patients with 1298CC and AC genotypes exhibit worse survival than those with the wild genotype (log rank, p = 0.001), whereas C677T genotypes do not affect patient survival (log rank, p = 0.92). MTHFR 677T allele carriers responded better to 5-FU-based chemotherapy than patients with the wild CC genotype (log rank, p = 0.05). The variant C allele of A1298C affects negatively the response to 5-FU-based chemotherapy (log rank, p = 0.009).

Conclusions

The variant allele of the C677T has a protective effect on CRC development, whereas the variant allele of the A1298C does not produce any effect on disease risk. Both MTHFR polymorphisms are relevant and independent factors of patient outcome after 5FU-based treatment of CRC, and MTHFR genotyping may be of predictive benefit in selecting treatment regimens.

Stern LL, Mason JB, Selhub J, Choi SW (2000) Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 9(8):849–853PubMed

Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B (2002) A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut 50(4):520–524CrossRefPubMed

van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B (2002) Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51(6):797–802CrossRefPubMed

Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R (1997) Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 57(6):1098–1102PubMed

Kim YI (1999) Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 10(2):66–88CrossRefPubMed

Bailey LB (2003) Folate, methyl-related nutrients, alcohol, and the MTHFR 677C → T polymorphism affect cancer risk: intake recommendations. J Nutr 133(11 Suppl 1):3748S–3753SPubMed

Ulrich CM, Bigler J, Bostick R, Fosdick L, Potter JD (2002) Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 62(12):3361–3364PubMed

Choi SW, Mason JB (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130(2):129–132PubMed

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111–113CrossRefPubMed

10.

Bagley PJ, Selhub J (1998) A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci U S A 95(22):13217–13220CrossRefPubMed

11.

Robien K, Ulrich CM (2003) 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk. Am J Epidemiol 157(7):571–582CrossRefPubMed

12.

Balley LB, Gregory JF (1999) Polymorphism of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risk and impact on folate requirement. J Nutr 129(5):919–922

13.

Brockton NT (2006) Localized depletion: the key to colorectal cancer risk mediated by MTHFR genotype and folate. Cancer Causes Control 17(8):1005–1016CrossRefPubMed

14.

Sharp L, Little J, Brockton NT, Cotton SC, Masson LF, Haites NE, Cassidy J (2008) Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case–control study in a population with relatively low folate intake. Br J Nutr 99(2):379–389CrossRefPubMed

15.

Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M (1999) Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomark Prev 8(6):513–518

16.

Ulrich CM, Kampman E, Bigler J, Schwartz SM, Chen C, Bostick R, Fosdick L, Beresford SA, Yasui Y, Potter JD (1999) Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomark Prev 8(8):659–668

17.

Marugame T, Tsuji E, Kiyohara C, Eguchi H, Oda T, Shinchi K, Kono S (2003) Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal adenomas. Int J Epidemiol 32(1):64–66CrossRefPubMed

18.

Giovannucci E, Chen J, Smith-Warner SA, Rimm EB, Fuchs CS, Palomeque C, Willett WC, Hunter DJ (2003) Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol Biomark Prev 12(10):970–979

19.

Yin G, Kono S, Toyomura K, Hagiwara T, Nagano J, Mizoue T, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Imaizumi N (2004) Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci 95(11):908–913CrossRefPubMed

20.

Toffoli G, Gafa R, Russo A, Lanza G, Dolcetti R, Sartor F, Libra M, Viel A, Boiocchi M (2003) Methylenetetrahydrofolate reductase 677C → T polymorphism and risk of proximal colon cancer in north Italy. Clin Cancer Res 9(2):743–748PubMed

21.

Keku T, Millikan R, Worley K, Winkel S, Eaton A, Biscocho L, Martin C, Sandler R (2002) 5,10-Methylenetetrahydrofolate reductase, codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev 11(12):1611–1620PubMed

22.

Plaschke J, Schwanebeck U, Pistorius S, Saeger HD, Schackert HK (2003) Methylenetetrahydrofolate reductase polymorphisms and risk of sporadic and hereditary colorectal cancer with or without microsatellite instability. Cancer Lett 191(2):179–185CrossRefPubMed

23.

Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, Forman D, Bishop DT, Wolf CR (2002) A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23(11):1839–1849CrossRefPubMed

24.

Lima CS, Nascimento H, Bonadia LC, Teori MT, Coy CS, Góes JR, Costa FF, Bertuzzo CS (2007) Polymorphisms in methylenetetrahydrofolate reductase gene (MTHFR) and the age of onset of sporadic colorectal adenocarcinoma. Int J Colorectal Dis 22(7):757–763CrossRefPubMed

25.

Weisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64(3):169–172CrossRefPubMed

26.

van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62(5):1044–1051CrossRefPubMed

27.

Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R (2002) The 1298A → C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156(2):409–415CrossRef

28.

Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM (2004) MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomark Prev 13(2):285–292CrossRef

29.

Kawakami K, Omura K, Kanehira E, Watanabe G (2001) Methylenetetrahydrofolate reductase polymorphism is associated with folate pool in gastrointestinal cancer tissue. Anticancer Res 21(1A):285–289PubMed

30.

Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) The effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96(2):134–144PubMedCrossRef

31.

González-Aguilera JJ, Palicio Herrero M, Maillo C, Moreno-Azcoita M, Fernández-Peralta AM (1999) Loss of heterozygosity of TP53 is not correlated with clinicopathological variables in sporadic colorectal carcinomas. Anticancer Res 19(2A):1325–1330PubMed

32.

González-Aguilera JJ, Oliart S, Moreno Azcoita M, Fernández-Peralta AM (2004) Simultaneous mutations in K-ras and TPp53 are indicative of poor prognosis in sporadic colorectal cancer. Am J Clin Oncol 27(1):39–45CrossRefPubMed

33.

Fernández-Peralta AM, Nejda N, Oliart S, Medina V, Moreno Azcoita M, González-Aguilera JJ (2005) Significance of mutations in TGFBRII and BAX in neoplastic progression and patient outcome in sporadic colorectal tumors with high-frequency microsatellite instability. Cancer Genet Cytogenet 157(1):18–24CrossRefPubMed

34.

Oliart S, Martinez-Santos C, Moreno Azcoita M, Cerquella C, Nejda N, Daimiel L, Iglesias D, Fernandez-Peralta MA, Gonzalez-Aguilera JJ (2006) Do MSI-L sporadic colorectal tumors develop through a “mild mutador pathway”. Am J Clin Oncol 29(4):364–370CrossRefPubMed

35.

Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, Spiegelman D, Willett WC, Hunter DJ (1996) A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 56(21):4862–4864PubMed

36.

Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998) Incidence and functional consequences of MLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870–6875CrossRefPubMed

37.

Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, Moore JH (2001) Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69(1):138–147CrossRefPubMed

38.

Ritchie MD, Hahn LW, Moore JH (2003) Power of multifactor dimensionality reduction for detecting gene–gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 24(2):150–157CrossRefPubMed

39.

Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction software for detecting gene–gene and gene–environment interactions. Bioinformatics 19(3):376–382CrossRefPubMed

40.

Giovannucci E, Stampfer MJ, Colditz GA, Rimm EB, Trichopoulos D, Rosner BA, Speizer FE, Willett WC (1993) Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 85(11):875–884CrossRefPubMed

41.

Saito M, Kato H, Tsuchida T, Konaka C (1994) Chemoprevention effects on bronchial squamous metaplasia by folate and vitamin B12 in heavy smokers. Chest 106(2):496–499CrossRefPubMed

42.

Chen J, Gammon MD, Chan W, Palomeque C, Wetmur JG, Kabat GC, Teitelbaum SL, Britton JA, Terry MB, Neugut AI, Santella RM (2005) One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. Cancer Res 65(4):1606–1614CrossRefPubMed

43.

Baron JA, Sandler RS, Haile RW, Mandel JS, Mott LA, Greenberg ER (1998) Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J Natl Cancer Inst 90(1):57–62CrossRefPubMed

44.

Chang SC, Lin PC, Lin JK, Yang SH, Wang HS, Li AF (2007) Role of MTHFR polymorphisms and folate levels in different phenotypes of sporadic colorectal cancers. Int J Colorectal Dis 22(5):483–489CrossRefPubMed

45.

Czernichow S, Noisette N, Blacher J, Galan P, Mennen L, Hercberg S, Ducimetière P (2005) Case for folic acid and vitamin B12 fortification in Europe. Semin Vasc Med 5(2):156–162CrossRefPubMed

46.

Pande M, Chen J, Amos CI, Lynch PM, Broaddus R, Frazier ML (2007) Influence of methylenetetrahydrofolate reductase gene polymorphisms C677T and A1298C on age-associated risk for colorectal cancer in a Caucasian lynch syndrome population. Cancer Epidemiol Biomarkers Prev 16(9):1753–1759CrossRefPubMed

47.

Sarbia M, Stahl M, von Weyhern C, Weirich G, Pühringer-Oppermann F (2006) The prognostic significance of genetic polymorphisms (methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, thymidilate synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer 94(2):203–207CrossRefPubMed

48.

Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R (2003) Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9(5):1611–1615PubMed

49.

Yamada K, Chen Z, Rozen R, Matthews RG (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A 98(26):14853–14858CrossRefPubMed

Titel: Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy
verfasst von: Antonia M. Fernández-Peralta
Lydia Daimiel
Nargisse Nejda
Daniel Iglesias
Vicente Medina Arana
Juan J. González-Aguilera
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: International Journal of Colorectal Disease / Ausgabe 2/2010
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-009-0779-y

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background and aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Mesocolic plane surgery: a reliable benchmark of surgical excellence?

Effect of hemorrhoidectomy on anorectal physiology

Erratum to: Comparison of a colonic J-pouch and transverse coloplasty pouch in patients with rectal cancer after an ultralow anterior resection using fecoflowmetric profiles

Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis

Serum interleukin-6 levels in colorectal cancer patients—a summary of published results

Krukenberg tumors of colorectal origin: a dismal outcome—experience of a tertiary center

Update Chirurgie